Polish Journal of Pathology Supplement
ISSN: -
Polish Journal of Pathology Supplement
Current supplement Archive Polish Journal of Pathology
Search
2/2021
 
Share:
Send email
Share:
Guidelines/recommendations

Leczenie nowotworów HER 2-dodatnich u pacjentek, u których nie uzyskano odpowiedzi po leczeniu neoadiuwantowym (choroba resztkowa) – współpraca onkologów klinicznych z patomorfologami

Michał Jarząb
1
,
Agnieszka Badora-Rybicka
1
,
Katarzyna Świderska
1

  1. Centrum Diagnostyki i Leczenia Chorób Piersi, Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie – Państwowy Instytut Badawczy, Oddział w Gliwicach
Online publish date: 2023/02/02
Article file
- SPJP-supl-3.pdf  [0.09 MB]
Get citation
 
 
1. Cortazar P, Geyer CEJ. Pathological complete response in neoadjuvant treatment of breast cancer. Ann Surg Oncol 2015; 22: 1441-1446.
2. von Minckwitz G, Huang C-S, Mano MS, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med 2019; 380: 617-628.
3. Delgado J, Vleminckx C, Sarac S, et al. The EMA review of trastuzumab emtansine (T-DM1) for the adjuvant treatment of adult patients with HER2-positive early breast cancer. ESMO Open 2021; 6: 100074.
4. Masuda N, Lee S-J, Ohtani S, et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med 2017; 376: 2147-2159.
5. Altundag K. Association between HER2 status in residual disease and sensitivity to trastuzumab emtansine. Ann Oncol [Internet]. 2021; 32: 1191.
6. Mamounas EP. Characteristics of residual invasive breast cancer after neoadjuvant therapy in the KATHERINE study. Ann Oncol 2021; 32: 1191-1192.
7. Yoshida A, Hayashi N, Suzuki K, et al. Change in HER2 status after neoadjuvant chemotherapy and the prognostic impact in patients with primary breast cancer. J Surg Oncol 2017; 116: 1021-1028.
8. Yau C, Osdoit M, van der Noordaa M, et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol 2022; 23: 149-160.
9. Denkert C, Lambertini C, Fasching PA, et al. Biomarker data from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer. J Clin Oncol 2020; 38 (15 suppl): 502–502.
10. Molinelli C, Parisi F, Razeti MG, et al. Trastuzumab emtansine (T-DM1) as adjuvant treatment of HER2-positive early breast cancer: safety and efficacy. Expert Rev Anticancer Ther 2022; 21: 241-250.
11. Conte PF, Schneeweiss A, Loibl S, et al. Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer. Cancer 2020; 126: 3132-3139.
12. Tolaney SM, Tayob N, Dang C, et al. Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. J Clin Oncol 2021; 39: 2375-2385.
13. O’Sullivan CC, Ballman KV, McCall L, et al. Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. Future Oncol 2021; 17: 4665-4676.
Copyright: © 2023 Polish Association of Pathologists and the Polish Branch of the International Academy of Pathology This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2026 Termedia Sp. z o.o.
Developed by Termedia.